First Week of February 2026 Options Trading For NewAmsterdam Pharma (NAMS)
Put Contract Analysis: The $17.50 put contract for NAMS stock offers a potential cost basis of $16.00 after collecting a premium, presenting an attractive option for investors compared to the current price of $18.11, with a 65% chance it may expire worthless.
Call Contract Overview: The $22.50 call contract allows investors to sell shares at a premium, potentially yielding a total return of 25.62% if exercised, while also having a 54% chance of expiring worthless, which would still allow retention of shares and collected premiums.
Trade with 70% Backtested Accuracy
Analyst Views on NAMS
About NAMS
About the author
NAMS Options Analysis: $30 Put Contract Offers Attractive Yield Boost
- Put Option Appeal: The $30.00 put option for NAMS has a current bid of 20 cents, and if an investor sells this contract, they commit to buying shares at $30.00, effectively lowering their cost basis to $29.80, which is about a 6% discount from the current price of $31.77, making it attractive for those looking to enter at a lower price.
- Yield Potential: Should the put option expire worthless, it would yield a 0.67% return on cash commitment, or an annualized yield of 3.86%, referred to as YieldBoost, highlighting the potential profitability of this contract.
- Call Option Returns: The $35.00 call option has a current bid of 40 cents, and if an investor buys shares at $31.77 and sells this call, they could achieve a total return of 11.43% if the stock is called away at expiration, showcasing the potential upside of this strategy.
- Risk Assessment: Current analytics suggest a 65% chance that the $30 put option will expire worthless, while the $35 call option has a 56% chance of doing the same, indicating that investors should carefully weigh the risks and rewards when selecting their options strategies.
NewAmsterdam Pharma Expects EMA Approval for Obicetrapib in 2H26
- Clinical Trial Progress: NewAmsterdam Pharma has enrolled its first patient in the RUBENS Phase 3 trial initiated in December 2025, which is expected to provide new treatment options for patients with metabolic syndrome, thereby enhancing the company's competitive position in the cardiovascular disease market.
- Strong Financial Position: As of December 31, 2025, NewAmsterdam reported a cash, cash equivalents, and marketable securities balance of approximately $729 million, which is sufficient to fund operations through the anticipated readout of the PREVAIL trial, ensuring future commercialization potential.
- Regulatory Advancements: The company is advancing its EMA applications for obicetrapib and its fixed-dose combination with Menarini, with an expected approval decision in 2H26, which will lay the groundwork for commercialization in the European market.
- Clear Strategic Goals: NewAmsterdam plans to initiate a clinical trial for Alzheimer's disease in 2026, further expanding the indications for obicetrapib, demonstrating the company's strategic positioning in both cardiovascular and neurodegenerative disease sectors.
NewAmsterdam Grants 40,000 Share Options to Attract New Hires
- Employee Incentive Plan: NewAmsterdam Pharma's Board Compensation Committee approved the grant of 40,000 inducement share options to two non-executive new hires, aimed at attracting talent and strengthening the team in line with the 2024 Inducement Plan.
- Option Details: The options have an exercise price of $39.61 per share, based on the closing price on December 1, 2025, and will vest over four years, designed to incentivize long-term employee commitment to the company.
- Market Reaction: This move not only enhances employee loyalty and motivation but may also attract more top talent in the future, thereby strengthening the company's competitiveness and innovation capabilities.
- Strategic Significance: By implementing the inducement option plan, NewAmsterdam demonstrates its commitment to talent, aiming to fill the market gap in cardiovascular disease treatment and drive long-term growth in the biopharmaceutical industry.
HC Wainwright & Co. Initiates Coverage on NewAmsterdam Pharma Co with a Buy Rating and Sets Price Target at $52
Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders, helping them stay informed and make timely decisions in the stock market.
Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, benefiting from exclusive stories and insights generated by Benzinga reporters.
Biotech and Medtech Stocks Surge in After-Hours Trading for Major Companies
Surge in Healthcare Stocks: On September 12, several healthcare and biotech stocks, including Penumbra, Check-Cap, Adaptimmune Therapeutics, and NewAmsterdam Pharma, saw significant after-hours trading gains, driven by strategic announcements and clinical milestones, despite some movements occurring without direct news.
Penumbra's Stock Performance: Penumbra Inc. experienced a rebound in after-hours trading, rising 6.28% to $289.86, following a decline during regular hours. The company raised its full-year revenue guidance and appointed a new president, indicating confidence in its growth trajectory.
Check-Cap's Merger Announcement: Check-Cap Ltd. saw its stock soar by 191.22% after announcing a merger with MBody AI, which aims to enhance its colorectal cancer screening technology with AI capabilities, potentially transforming its strategic direction.
NewAmsterdam Pharma's Regulatory Progress: NewAmsterdam Pharma's shares rose 8.23% after-hours, driven by positive investor sentiment regarding its lead candidate obicetrapib and recent regulatory milestones, including accepted Marketing Authorization Applications by the EMA and promising trial data related to Alzheimer's disease biomarkers.
NewAmsterdam Pharma Company N.V. (NAMS) Shares Insights at Citi's Biopharma Back to School Conference Transcript
Conference Overview: NewAmsterdam Pharma participated in the Citi's Biopharma Back to School Conference, highlighting their recent achievements and ongoing projects in the biopharmaceutical sector.
Phase III Data Highlights: CEO Michael Davidson discussed the successful Phase III BROADWAY trial, which demonstrated significant LDL lowering and a 21% reduction in major adverse cardiovascular events (MACE), alongside recent publications in prestigious medical journals.
NAMS Options Analysis: $30 Put Contract Offers Attractive Yield Boost
- Put Option Appeal: The $30.00 put option for NAMS has a current bid of 20 cents, and if an investor sells this contract, they commit to buying shares at $30.00, effectively lowering their cost basis to $29.80, which is about a 6% discount from the current price of $31.77, making it attractive for those looking to enter at a lower price.
- Yield Potential: Should the put option expire worthless, it would yield a 0.67% return on cash commitment, or an annualized yield of 3.86%, referred to as YieldBoost, highlighting the potential profitability of this contract.
- Call Option Returns: The $35.00 call option has a current bid of 40 cents, and if an investor buys shares at $31.77 and sells this call, they could achieve a total return of 11.43% if the stock is called away at expiration, showcasing the potential upside of this strategy.
- Risk Assessment: Current analytics suggest a 65% chance that the $30 put option will expire worthless, while the $35 call option has a 56% chance of doing the same, indicating that investors should carefully weigh the risks and rewards when selecting their options strategies.
NewAmsterdam Pharma Expects EMA Approval for Obicetrapib in 2H26
- Clinical Trial Progress: NewAmsterdam Pharma has enrolled its first patient in the RUBENS Phase 3 trial initiated in December 2025, which is expected to provide new treatment options for patients with metabolic syndrome, thereby enhancing the company's competitive position in the cardiovascular disease market.
- Strong Financial Position: As of December 31, 2025, NewAmsterdam reported a cash, cash equivalents, and marketable securities balance of approximately $729 million, which is sufficient to fund operations through the anticipated readout of the PREVAIL trial, ensuring future commercialization potential.
- Regulatory Advancements: The company is advancing its EMA applications for obicetrapib and its fixed-dose combination with Menarini, with an expected approval decision in 2H26, which will lay the groundwork for commercialization in the European market.
- Clear Strategic Goals: NewAmsterdam plans to initiate a clinical trial for Alzheimer's disease in 2026, further expanding the indications for obicetrapib, demonstrating the company's strategic positioning in both cardiovascular and neurodegenerative disease sectors.
NewAmsterdam Grants 40,000 Share Options to Attract New Hires
- Employee Incentive Plan: NewAmsterdam Pharma's Board Compensation Committee approved the grant of 40,000 inducement share options to two non-executive new hires, aimed at attracting talent and strengthening the team in line with the 2024 Inducement Plan.
- Option Details: The options have an exercise price of $39.61 per share, based on the closing price on December 1, 2025, and will vest over four years, designed to incentivize long-term employee commitment to the company.
- Market Reaction: This move not only enhances employee loyalty and motivation but may also attract more top talent in the future, thereby strengthening the company's competitiveness and innovation capabilities.
- Strategic Significance: By implementing the inducement option plan, NewAmsterdam demonstrates its commitment to talent, aiming to fill the market gap in cardiovascular disease treatment and drive long-term growth in the biopharmaceutical industry.
HC Wainwright & Co. Initiates Coverage on NewAmsterdam Pharma Co with a Buy Rating and Sets Price Target at $52
Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders, helping them stay informed and make timely decisions in the stock market.
Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, benefiting from exclusive stories and insights generated by Benzinga reporters.
Biotech and Medtech Stocks Surge in After-Hours Trading for Major Companies
Surge in Healthcare Stocks: On September 12, several healthcare and biotech stocks, including Penumbra, Check-Cap, Adaptimmune Therapeutics, and NewAmsterdam Pharma, saw significant after-hours trading gains, driven by strategic announcements and clinical milestones, despite some movements occurring without direct news.
Penumbra's Stock Performance: Penumbra Inc. experienced a rebound in after-hours trading, rising 6.28% to $289.86, following a decline during regular hours. The company raised its full-year revenue guidance and appointed a new president, indicating confidence in its growth trajectory.
Check-Cap's Merger Announcement: Check-Cap Ltd. saw its stock soar by 191.22% after announcing a merger with MBody AI, which aims to enhance its colorectal cancer screening technology with AI capabilities, potentially transforming its strategic direction.
NewAmsterdam Pharma's Regulatory Progress: NewAmsterdam Pharma's shares rose 8.23% after-hours, driven by positive investor sentiment regarding its lead candidate obicetrapib and recent regulatory milestones, including accepted Marketing Authorization Applications by the EMA and promising trial data related to Alzheimer's disease biomarkers.
NewAmsterdam Pharma Company N.V. (NAMS) Shares Insights at Citi's Biopharma Back to School Conference Transcript
Conference Overview: NewAmsterdam Pharma participated in the Citi's Biopharma Back to School Conference, highlighting their recent achievements and ongoing projects in the biopharmaceutical sector.
Phase III Data Highlights: CEO Michael Davidson discussed the successful Phase III BROADWAY trial, which demonstrated significant LDL lowering and a 21% reduction in major adverse cardiovascular events (MACE), alongside recent publications in prestigious medical journals.
